• Hotline +852 3480 8393

Logo
EN
繁中
  • Home
  • About Us
    • Background
    • Immunotherapy in Japan
    • Immunotherapy in Hong Kong
    • Specialist Consultation
  • Immune Cell Therapy
    • What Is Immune Cell Therapy?
    • Dendritic Cell (DC) Therapy
    • Lymphokine-Activated Killer Cell (LAK) Thearpy
    • Natural Killer Cell (NK) Therapy
    • Success Rate
    • Side Effects
    • Fees
  • Doctor
    • Japan
  • Our News
  • Contact Us
  • EN
    • 繁中
Home > Our News > News > Dendritic Cell Vaccine Therapy: Insights from Dr. Yoichi Kato, Immunotherapy Specialist

Dendritic Cell Vaccine Therapy: Insights from Dr. Yoichi Kato, Immunotherapy Specialist

  • Dr. Yoichi Kato
  • 2023-08-09
  • 4205 View

The Role of Dendritic Cells: Commanders of the Immune System

In the human body, monocytes are produced in the bone marrow, travel through the bloodstream, and develop into dendritic cells in locations such as the lymph nodes. Serving as the “command center” of our immune system, dendritic cells collaborate with various lymphocytes to identify and combat foreign invaders, including viruses. Thanks to this coordinated immune response, we can continuously fend off new pathogens and maintain our health.


For instance, once you catch a cold, dendritic cells can record the identity of the virus. Even if your family members later contract the same strain, you may stay protected from reinfection. Because young children’s dendritic cells are not fully mature and older adults experience a decrease in dendritic cell quantity, children are more prone to infections, while seniors are at higher risk for malignancies.

Dr. Yoichi Kato

Dr. Yoichi Kato


A Revolutionary Prospect: Harnessing Dendritic Cell Function

If we learn to direct or activate dendritic cells effectively, the potential to treat and even prevent various diseases becomes feasible. By administering dendritic cell vaccines early in life, we may ward off infections and malignant cells. For adults over thirty, regular vaccinations could maintain the lower incidence of serious diseases typically seen in younger populations. Malignancies often arise when the immune system fails to fully recognize abnormal cells, whereas autoimmune diseases occur when the immune system mistakenly treats healthy cells as enemies.


Today, researchers can cultivate dendritic cells in laboratories, equip them with critical therapeutic information against specific diseases, and reintroduce them into the body for targeted treatment. Our medical experts stand at the forefront of this groundbreaking therapy, determined to usher it into mainstream clinical practice.


Obtaining Dendritic Cells from the Human Body

From Initial Setbacks to Breakthroughs

Earlier studies that used only about 50 milliliters of blood to induce dendritic cells saw limited results. Consequently, researchers were initially discouraged. When they increased the blood volume collected to about 5,000 milliliters—close to a person’s entire circulating blood volume—the number of cultivated dendritic cells expanded a hundredfold, and measurable therapeutic benefits emerged.


Apheresis Procedure

Apheresis is performed by extracting around 50 milliliters of blood per minute, isolating about 1 milliliter of liquid containing a high concentration of monocytes, and immediately returning the remaining 49 milliliters to the body. This cycle repeats until sufficient monocytes are collected. In a controlled laboratory environment, these monocytes are then exposed to growth factors such as GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor), IL-4 (Interleukin-4), and TNF-α (Tumor Necrosis Factor-Alpha) to promote differentiation into immature dendritic cells. Next, peptides or other antigens are introduced, prompting the dendritic cells to mature and acquire “memory” against tumor cells. These activated dendritic cells are then administered back to the patient through multiple injections over several weeks, typically weekly or bi-weekly, subject to the physician’s assessment.


Outline of the Therapeutic Process

1. Apheresis – Employ specialized cell separation techniques to collect monocytes.

2. Cultivation & Differentiation – Introduce growth factors to guide monocytes into immature dendritic cells.

3. Maturation & Activation – Expose immature dendritic cells to specific antigens, so they develop a precise response against target cells.

4. Injection – Reintroduce the mature dendritic cells into the patient’s body, in multiple sessions, to sustain an effective immune response.

This therapy requires oversight from a specialized medical team and is tailored to each patient’s condition.


Accessing Treatment with Dr. Yoichi Kato

The Asia Immunotherapy Center in Tsim Sha Tsui, Hong Kong, collaborates closely with Dr. Yoichi Kato. Patients can simply submit their medical records to the center, which will handle translation and coordinate consultations with Dr. Kato. Once a treatment schedule is in place, detailed information—including procedures, costs, and itinerary—will be provided without the patient needing to travel to Japan beforehand, allowing them to make fully informed decisions from the comfort of home.


Asia Immunotherapy


Previous:The Key Differences Among DC, LAK, and NK Immunotherapies—and How to Choose Next:Japan’s Leading Expert in Immunotherapy: Dr. Yoichi Kato

Category

  • News 18

Latest Articles

  • YouTube channel “珍心活” interviews Dr. Yoichi Kat
    2025-08-03
  • Celebrity Host Cheng Tan Shui’s Exclusive Interview with Connie Lam: How to Choose the Right Doctor in Japan for Immunocellular Therapy
    2025-01-10
  • Hong Kong Actor Carlos Chan Accompanies His Mother to Shin-Yokohama Kato Clinic for Immunotherapy, Expresses Gratitude to Dr. Yoichi Kato
    2024-07-03
  • Yoshida Family Donates 12,000 Square Feet of Land to Dr. Yoichi Kato
    2024-04-05
  • がんの先進医療 | 2025 Jan. vol. 56
    2025-04-02
  • Dr. Kato’s New Medical Facility Nears Completion
    2024-01-19
  • Dr. Kato’s Expert Team: Meet the Visionary Scientist Behind the “Magic Lab”
    2023-11-10
  • “Humanity’s Innate Immune Power Surpasses Any Manufactured Drug” – Dr. Yoichi Kato, Pioneer in Immunotherapy
    2023-11-03
  • Japanese Media Interview with a Renowned Physician: “The Current Status of Late-Stage Healthcare in Japan”
    2023-10-27
  • The Key Differences Among DC, LAK, and NK Immunotherapies—and How to Choose
    2023-10-19
  • Dendritic Cell Vaccine Therapy: Insights from Dr. Yoichi Kato, Immunotherapy Specialist
    2023-08-09
  • Japan’s Leading Expert in Immunotherapy: Dr. Yoichi Kato
    2023-07-27
  • Natural Killer Cells in the Immune System: Your Body's First Line of Defense
    2025-10-13
  • Dendritic Cells Immune Response: The Commanders of Your Immune System
    2025-10-13
  • Dendritic Cells: Defining the Commanders of the Immune System and Their Role in Immunotherapy
    2025-10-13
  • Dendritic Cell Therapy Success Rate: An Evidence-Based Analysis
    2025-10-13
  • Dendritic Cell Therapy: An Advanced Cancer Treatment for Stage 4 Patients
    2025-10-13
All Articles
Logo
  • Email:info@asiaimmune.com
  • Tel / WhatsApp:+852 3480 8393
  • Wechat:aicl_hk
  • Office hours:Mon to Fri | 9am to 6pm

Immune Cell Therapy

  • What Is Immune Cell Therapy?
  • Dendritic Cell (DC) Therapy
  • Lymphokine-Activated Killer Cell (LAK) Thearpy
  • Natural Killer Cell (NK) Therapy
  • Success Rate
  • Side Effects
  • Fees

Address

  • Room 1202, 12/F, Hing Wai Building, 36 Queen's Road Central, Central, HK (📍Goolge Map)
  • +852 3480 8393

Copyright © 2026. Designed by Asia Immunotherapy Company Limited.